These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
8. Amyloid-PET Levels in the Precuneus and Posterior Cingulate Cortices Are Associated with Executive Function Scores in Preclinical Alzheimer's Disease Prior to Overt Global Amyloid Positivity. Ali DG; Bahrani AA; Barber JM; El Khouli RH; Gold BT; Harp JP; Jiang Y; Wilcock DM; Jicha GA J Alzheimers Dis; 2022; 88(3):1127-1135. PubMed ID: 35754276 [TBL] [Abstract][Full Text] [Related]
9. Automated quantification of 18F-flutemetamol PET activity for categorizing scans as negative or positive for brain amyloid: concordance with visual image reads. Thurfjell L; Lilja J; Lundqvist R; Buckley C; Smith A; Vandenberghe R; Sherwin P J Nucl Med; 2014 Oct; 55(10):1623-8. PubMed ID: 25146124 [TBL] [Abstract][Full Text] [Related]
11. Amyloid-β assessed by florbetapir F 18 PET and 18-month cognitive decline: a multicenter study. Doraiswamy PM; Sperling RA; Coleman RE; Johnson KA; Reiman EM; Davis MD; Grundman M; Sabbagh MN; Sadowsky CH; Fleisher AS; Carpenter A; Clark CM; Joshi AD; Mintun MA; Skovronsky DM; Pontecorvo MJ; Neurology; 2012 Oct; 79(16):1636-44. PubMed ID: 22786606 [TBL] [Abstract][Full Text] [Related]
12. AD molecular: PET amyloid imaging across the Alzheimer's disease spectrum: From disease mechanisms to prevention. Meyer PF; McSweeney M; Gonneaud J; Villeneuve S Prog Mol Biol Transl Sci; 2019; 165():63-106. PubMed ID: 31481172 [TBL] [Abstract][Full Text] [Related]
13. The bivariate distribution of amyloid-β and tau: relationship with established neurocognitive clinical syndromes. Jack CR; Wiste HJ; Botha H; Weigand SD; Therneau TM; Knopman DS; Graff-Radford J; Jones DT; Ferman TJ; Boeve BF; Kantarci K; Lowe VJ; Vemuri P; Mielke MM; Fields JA; Machulda MM; Schwarz CG; Senjem ML; Gunter JL; Petersen RC Brain; 2019 Oct; 142(10):3230-3242. PubMed ID: 31501889 [TBL] [Abstract][Full Text] [Related]
15. 18F PET with flutemetamol for the early diagnosis of Alzheimer's disease dementia and other dementias in people with mild cognitive impairment (MCI). Martínez G; Vernooij RW; Fuentes Padilla P; Zamora J; Flicker L; Bonfill Cosp X Cochrane Database Syst Rev; 2017 Nov; 11(11):CD012884. PubMed ID: 29164602 [TBL] [Abstract][Full Text] [Related]
16. Evaluation of PiB visual interpretation with CSF Aβ and longitudinal SUVR in J-ADNI study. Okada Y; Kato T; Iwata K; Kimura Y; Nakamura A; Hattori H; Toyama H; Ishii K; Ishii K; Senda M; Ito K; Iwatsubo T; Ann Nucl Med; 2020 Feb; 34(2):108-118. PubMed ID: 31749127 [TBL] [Abstract][Full Text] [Related]
17. PET measurement of longitudinal amyloid load identifies the earliest stages of amyloid-beta accumulation during Alzheimer's disease progression in Down syndrome. Zammit MD; Tudorascu DL; Laymon CM; Hartley SL; Zaman SH; Ances BM; Johnson SC; Stone CK; Mathis CA; Klunk WE; Cohen AD; Handen BL; Christian BT Neuroimage; 2021 Mar; 228():117728. PubMed ID: 33421595 [TBL] [Abstract][Full Text] [Related]
18. APOE Effect on Amyloid-β PET Spatial Distribution, Deposition Rate, and Cut-Points. Toledo JB; Habes M; Sotiras A; Bjerke M; Fan Y; Weiner MW; Shaw LM; Davatzikos C; Trojanowski JQ; J Alzheimers Dis; 2019; 69(3):783-793. PubMed ID: 31127775 [TBL] [Abstract][Full Text] [Related]
19. Relationships between flortaucipir PET tau binding and amyloid burden, clinical diagnosis, age and cognition. Pontecorvo MJ; Devous MD; Navitsky M; Lu M; Salloway S; Schaerf FW; Jennings D; Arora AK; McGeehan A; Lim NC; Xiong H; Joshi AD; Siderowf A; Mintun MA; Brain; 2017 Mar; 140(3):748-763. PubMed ID: 28077397 [TBL] [Abstract][Full Text] [Related]